anti-IL-23 monoclonal antibody

临床试验

计划入组 13 人 · 首次发布于 2021 年 2 月 3 日

已完成

NCT01845987

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

计划入组 49 人 · 首次发布于 2013 年 5 月 3 日

撤回

NCT04084665

Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.

首次发布于 2019 年 9 月 10 日

药物

查看全部 5308 →

Anti-IL-23 monoclonal antibody(Merck Sharp & Dohme Corp.)

Biotech

Approved

Mirikizumab(Omvoh)

相关疾病：Moderately to Severely Active Ulcerative Colitis

Rx

anti-IL-23 receptor antibody fragment

机构

查看全部 266 →

Cambridge Antibody Technology

New Zealand

Simcha Il 18, Inc.

United States

Latticon Antibody Therapeutics, Inc

United States

资讯

查看全部 11148 →

去年

FibroBiologics Reports Breakthrough Results for Single-Dose Fibroblast Spheroid Therapy in Chronic Psoriasis

去年

Spyre Therapeutics Initiates Phase 1 Trial of Novel Long-Acting IL-23 Antibody for IBD Treatment

去年

临床试验

Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.

药物

Anti-IL-23 monoclonal antibody(Merck Sharp & Dohme Corp.)

Mirikizumab(Omvoh)

anti-IL-23 receptor antibody fragment

机构

Cambridge Antibody Technology

Simcha Il 18, Inc.

Latticon Antibody Therapeutics, Inc

资讯

FibroBiologics Reports Breakthrough Results for Single-Dose Fibroblast Spheroid Therapy in Chronic Psoriasis

Spyre Therapeutics Initiates Phase 1 Trial of Novel Long-Acting IL-23 Antibody for IBD Treatment

Spyre Therapeutics Accelerates SPY003 (IL-23p19) Clinical Timelines Based on Preclinical Data